Besides bariatric surgery, many pharmacological agents available for treating people with diabetes and obesity work by manipulating the gut-derived hormone glucagon-like peptide-1 (GLP-1), altogether highlighting the importance of the gastrointestinal (GI) tract in developing interventions for diabetes and obesity. Here, GLP1R is linked to obesity disorder.